摘要
近年来肾癌发病率逐年升高。随着研究的深入,对于肾癌发生发展机制、肿瘤生物学特征有了更多的了解。目前临床常用的肾癌预后判断方法是以临床指标为主的预后预测模型。在传统酪氨酸激酶抑制剂的基础上,近年来以免疫检查点抑制剂为代表的新型药物在肾癌治疗领域取得了巨大成功。随着越来越多与肾癌预后及疗效相关分子标记物的发现,有望为肾癌预后预测和治疗方案选择提供更多参考。
The prevalence of renal cell carcinoma is increasing in recent years.With the development of research,we know more about the mechanism and biological characteristics of renal cell carcinoma.Currently,the most used prognosis evaluation methods are clinical factors based prognostic prediction models.New drugs,typified by the checkpoint inhibitors,have achieved great success in the treatment of renal cell carcinoma,on the basis of traditional tyrosine kinase inhibitor.With recognition of more prognosis and treatment related biomarkers,directive role for the prognosis prediction and treatment options could be expected.
作者
龚侃
唐琦
周靖程
Kan Gong;Qi Tang;Jingcheng Zhou(Department of Urology,Peking University First Hospital,Institute of Urology,National Urological Cancer Center,Beijing 100034,China)
出处
《中华医学杂志》
CAS
CSCD
北大核心
2021年第46期3767-3770,共4页
National Medical Journal of China
关键词
肾肿瘤
癌
肾细胞
精准医学
分子标记物
Kidney neoplasms
Carcinoma,renal cell
Precision medicine
Biomarkers
